Physician profile
Brian Beck
NPI 1154642205
$22,114.85
in general payments reported to CMS, 2019-2025
67 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $2,341 · 2021: $2,757 · 2022: $2,618 · 2023: $1,624 · 2024: $591 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,500 · Food and Beverage: $2,948 · Consulting Fee: $2,650 · Travel and Lodging: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,500.00 |
| Food and Beverage | $2,947.98 |
| Consulting Fee | $2,650.00 |
| Travel and Lodging | $1,694.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $7,804.80 | 2020-2025 | Xcopri |
| Argenx US, INC. | $3,172.20 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $1,384.96 | 2019-2022 | |
| Abbvie INC. | $1,223.17 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Amgen INC. | $874.36 | 2019-2024 | Aimovig, Uplizna |
| Ucb, INC. | $784.84 | 2019-2024 | Zilbrysq, Rystiggo |
| Biogen, INC. | $725.24 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Csl Behring | $377.27 | 2020-2023 | Privigen, Hizentra |
| Acadia Pharmaceuticals INC | $361.53 | 2019-2024 | Nuplazid |
| Lilly USA, LLC | $357.12 | 2019-2023 | Reyvow, Emgality |
| Teva Pharmaceuticals USA, INC. | $348.62 | 2019-2023 | Austedo |
| Pfizer INC. | $326.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $324.29 | 2019-2022 | |
| Genzyme Corporation | $314.30 | 2019-2023 | |
| Upsher-Smith Laboratories LLC | $294.48 | 2019-2023 |
Show all 66 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.